Renal Cell Carcinoma: Clinical Management Steven C. Campbell Editor - nouveau livre

Livre dans la base de données depuis 2012-02-27T11:39:46+01:00 (Paris)
Page de détail modifiée en dernier sur 2023-10-16T20:11:21+02:00 (Paris)
ISBN/EAN: 162703062X

ISBN - Autres types d'écriture:
1-62703-062-X, 978-1-62703-062-5
Autres types d'écriture et termes associés:
Auteur du livre: campbell brian
Titre du livre: management clinical, renal cell carcinoma

Données de l'éditeur

Auteur: Steven C. Campbell; Brian I. Rini
Titre: Current Clinical Urology; Renal Cell Carcinoma - Clinical Management
Editeur: Humana; Humana Press
362 Pages
Date de parution: 2012-09-25
Totowa; NJ; US
Langue: Anglais
106,99 € (DE)
130,00 CHF (CH)
Available
XI, 362 p.

EA; E107; eBook; Nonbooks, PBS / Medizin/Klinische Fächer; Urologie, Medizin des Harn- und Geschlechtsapparats; Verstehen; Familial RCC; Multiplanar CT; RAD Nx; Radiographic imaging; Targeted therapy; Thermal ablation; cT1 renal tumors; B; Urology; Oncology; Medicine; Onkologie; BB

provides a comprehensive, state-of-the art review of this field, and will serve as a valuable resource for clinicians, surgeons and researchers with an interest in kidney cancer. The volume reviews new data about risk factors for the disease, profiles the new staging system for renal cell carcinoma (RCC), highlights our current understanding of familial syndromes of RCC and their molecular genetics, and provides new perspectives about imaging of renal tumors. For localized disease, a greater appreciation of nephron-sparing approaches and the importance of preservation of renal function is discussed in detail. Advances in surgical techniques are highlighted. For metastatic disease, the molecular biology of kidney cancer is reviewed in a concise and understandable manner, including the data that has fostered novel targeted approaches that have revolutionized management. The several landmark phase III targeted therapy trials published in the last few years are placed in context with respect to current management. Integration of surgery and systemic therapy through cytoreductive and consolidative approaches has yielded provocative data that promises to further advance the field, and major advances in this domain are also be discussed.

From the book reviews:

“Editors S. Campbell and B. Rini, with the support of 40 experts, aimed to come out with an update on recent innovations, focusing on clinical implications. … A very well-illustrated chapter dealt with various pathological aspects of RCC, including molecular genetics, while another chapter focused on family diseases. … This textbook offers practical information which is of special interest to all urologists and oncologists involved in RCC management.” (European Urology Today, Vol. 25 (3), June-July, 2013)

“This is a concise but comprehensive review of renal cell carcinoma from etiology and risk factors to medical and surgical management. … This is an excellent resource for any practitioner with an interest in renal cell carcinoma. … this book would appeal to general oncologists, urologists, general surgeons, radiologists, pathologists, nephrologists, internists, family practitioners, fellows, residents, and students. … It is thorough, clearly written, and logically presented.” (Jean Hoffman-Censits, Doody’s Book Reviews, February, 2013)

provides a comprehensive, state-of-the art review of this field, and will serve as a valuable resource for clinicians, surgeons and researchers with an interest in kidney cancer. The volume reviews new data about risk factors for the disease, profiles the new staging system for renal cell carcinoma (RCC), highlights our current understanding of familial syndromes of RCC and their molecular genetics, and provides new perspectives about imaging of renal tumors. For localized disease, a greater appreciation of nephron-sparing approaches and the importance of preservation of renal function is discussed in detail. Advances in surgical techniques are highlighted. For metastatic disease, the molecular biology of kidney cancer is reviewed in a concise and understandable manner, including the data that has fostered novel targeted approaches that have revolutionized management. The several landmark phase III targeted therapy trials published in the last few years are placed in context with respect to current management.